Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

What Is An Acceptable Drug Discount? DOJ and Industry Disagree

Executive Summary

Government contends a price reduction is the only discount exception to the Anti-Kickback Statute; PhRMA says this interpretation puts companies at risk of criminal liability for other discount arrangements.

You may also be interested in...



FTC’s New Commissioner, Alvaro Bedoya, May Bolster Tougher Stance On Pharma Oversight

Democrats gain majority on Federal Trade Commission with Bedoya’s swearing in. His positions on technology and digital privacy suggest he will align with commissioners who have advocated stricter review of pharma mergers.

Accelerated Approval, Clinical Trial Diversity Provisions Left Out Of Senate User Fee Bill

Two of the most prominent features of the House package are not addressed in the Senate measure, which predominantly focuses on cosmetics, dietary supplements and laboratory developed tests. The absence of competing proposals suggests a smooth conference process.

Neuroblastoma Drug Development: Potential Surrogate Endpoint Gets US FDA Panel Backing

Advisory committee supports further research on end-of-induction response as an early interim clinical endpoint for drugs in treatment of high-risk neuroblastoma. FDA has approved two drugs for this rare disease in children, who have a 40-50% chance of long-term survival.

Topics

Related Companies

UsernamePublicRestriction

Register

PS119330

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel